Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Health Yuan and Qi Yuan Bio have reached a new drug licensing cooperation for an inhaled PDE4 inhibitor, jointly promoting innovative drug development.

Published Time:

2024-11-25

On November 22, 2024, Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Joincare"), an innovative research-oriented comprehensive pharmaceutical group, and QiYuan Bio (Hangzhou) Co., Ltd. (hereinafter referred to as "QiYuan Bio"), which focuses on the development of innovative drugs for autoimmune diseases, jointly announced that the two parties have reached a licensing cooperation agreement for an innovative drug—an inhaled PDE4 inhibitor for chronic obstructive pulmonary disease (COPD). According to the agreement, Joincare obtains the right to develop and commercialize this innovative inhaled drug in China, while QiYuan Bio retains the right to develop the topical cream. Both parties will jointly promote the development and market promotion of this innovative drug.

 

This innovative PDE4 inhibitor, as a drug with a novel mechanism in the COPD field, can precisely act on COPD inflammatory cells, and through anti-inflammatory, improving lung function, and regulating immune responses, it directly targets lung lesions and effectively reduces the frequency of acute COPD exacerbations. Inhaled administration significantly reduces systemic drug exposure, ensuring treatment safety while reducing the risk of systemic side effects. This is also the first PDE4 inhaled formulation pipeline launched by a Chinese company. In addition, the broad-spectrum anti-inflammatory properties of PDE4 inhibitors also show therapeutic potential for diseases such as asthma.

 

Joincare, as a leading comprehensive pharmaceutical company in China, has strong R&D capabilities and extensive market promotion experience. The company has a significant advantage in the field of inhaled formulations and has successfully developed and commercialized a number of respiratory disease treatment drugs. This cooperation will fully utilize Joincare's expertise and market resources in the field of inhaled formulations to accelerate the R&D process of this new inhaled drug and bring new treatment options to patients as soon as possible.

 

Mr. Lin Nanqi, President of Joincare, said: "Joincare is committed to making breakthroughs in the field of innovative drugs. Cooperation with QiYuan Bio can fully tap the value of this innovative drug, achieving mutual benefit for both companies. The collaborative development of this inhaled PDE4 inhibitor will further enrich Joincare's respiratory drug R&D pipeline, especially in the treatment of asthma and COPD." We are full of expectations for the potential of this drug. We will fully support and accelerate its clinical research process to achieve commercialization as soon as possible and bring safer and more effective treatment options to patients with respiratory diseases."

 

Ding Shizhe, CEO of QiYuan Bio, said: "QiYuan Bio focuses on the development of drugs in the field of autoimmune diseases and has achieved certain results and advantages. Our team looks forward to continuously exploring the clinical value of this product in more areas through this cooperation, benefiting more patients. This licensing agreement marks the achievement of QiYuan Bio's first strategic cooperation, an ideal beginning, and we expect this cooperation to bring better development and new catalysis to both parties. QiYuan Bio currently mainly focuses on oral and topical drug delivery methods, while Joincare is second to none in inhaled formulation technology in China. Therefore, this product has great potential in future new clinical applications."

 

 

 

About Joincare:

Founded in 1992, Joincare (600380.SH) is an innovative, research-oriented comprehensive pharmaceutical group. It owns two large listed companies, Joincare and Lizhu Pharmaceutical, and more than 20 major subsidiaries. The company has always adhered to technological innovation as its strategic foundation and aims to drive innovation with both innovative drugs and high-barrier complex formulation technology platforms. It has a rich and diverse product matrix and R&D drug pipeline in areas with significant clinical needs, such as respiratory, analgesia, digestive tract, assisted reproduction, mental health, and oncology. It has a significant advantage in the field of inhaled formulations and has successfully developed and commercialized a number of respiratory disease treatment drugs, making it a leader in the domestic respiratory formulation field.

 

About QiYuan Bio:

QiYuan Bio (Hangzhou) Co., Ltd. is an innovative pharmaceutical company focusing on the development of innovative drugs for autoimmune diseases. Headquartered in Hangzhou, it has received angel investment from Benda Fund and support from multiple professional capitals, and has reached a strategic cooperation with Benda Pharmaceutical to jointly promote the clinical development of the company's drugs. Adhering to the values of "embracing competition, relentless pursuit, and frank dedication," the company has established a transformation team with successful experience in all stages of new drug development. The company's globally patented Class 1 innovative drugs QY201, QY101, and QY211 have all entered the clinical stage, with QY201 having initiated Phase III clinical trials for atopic dermatitis. The company is committed to becoming a leader in the development of innovative drugs for autoimmune diseases.